Bank of America Have Target Price per Share $200 on GW Pharmaceuticals (NASDAQ:GWPH). Equity Analysts Didn’t Change firms “Buy” rating.

June 27, 2018 - By Jimmy Cauthen

Reiterated GW Pharmaceuticals (NASDAQ:GWPH) Rating.

On 26 June an analyst report was issued to investors and clients on GW Pharmaceuticals (NASDAQ:GWPH) of its “Buy” Rating maintained by stock research analysts at Bank of America. The market cap company was given $200 target price that gives 43.53 % upside potential from the last stock close price.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

A total of 5 analysts rate GW Pharma (NASDAQ:GWPH) as follows: 5 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:GWPH) has 10 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Tuesday, June 26 the firm earned “Buy” rating by Bank of America. The company rating was maintained by Cantor Fitzgerald on Monday, June 25. On Tuesday, January 23 the firm earned “Buy” rating by Leerink Swann. On Thursday, December 28 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given by Leerink Swann. On Wednesday, April 18 the rating was maintained by Cowen & Co with “Buy”. On Tuesday, June 26 the firm has “Buy” rating given by Goldman Sachs. On Tuesday, February 6 Bank of America maintained the shares of GWPH in report with “Buy” rating. On Tuesday, February 6 the company was maintained by Leerink Swann. In Monday, February 5 report Cantor Fitzgerald maintained it with “Buy” rating and $192.0 target. On Tuesday, April 17 the stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given by Cantor Fitzgerald.

GWPH reached $139.34 during the last trading session after $7.17 change.GW Pharmaceuticals plc is uptrending after having risen 49.14% since June 27, 2017. GWPH has 682,486 volume or 54.71% up from normal. The stock outperformed the S&P 500 by 36.57%.

On August, 6 is expected GW Pharmaceuticals plc (NASDAQ:GWPH)’s earnings report, as reported by RTT. The earnings per share diference is $0.32 or 15.46 % down from last years number. Previous year: $-2.07; Analysts forcast: $-2.39. Wall Street now predicts -23.40 % EPS growth despite GW Pharmaceuticals plc previous quarter’s EPS of $-3.12.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.The company has $3.93 billion market cap. The firm operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development.Currently it has negative earnings. The Company’s lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

For more GW Pharmaceuticals plc (NASDAQ:GWPH) news announced briefly go to: Streetinsider.com, Seekingalpha.com, Investorplace.com, Benzinga.com or Benzinga.com. The titles are as follows: “GW Pharma (GWPH): Epidiolex Approved…But Expected – Goldman Sachs” announced on June 26, 2018, “GW Pharmaceuticals: Value Beyond Epidiolex?” on June 04, 2018, “Here’s the Reason that GWPH Stock Tumbled Despite Regulatory Victory” with a publish date: June 27, 2018, “GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis” and the last “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” with publication date: June 26, 2018.

GW Pharmaceuticals plc (NASDAQ:GWPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.